Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease
- 13 July 2009
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 157 (6), 892-906
- https://doi.org/10.1111/j.1476-5381.2009.00170.x
Abstract
Phosphodiesterase (PDE)4, and to a lesser extent, PDE3/4 inhibitors have attracted considerable interest as potential therapeutic agents for diseases including chronic obstructive pulmonary disease. Indeed, ibudilast and theophylline are utilized clinically, and roflumilast is in late-stage clinical development. Unfortunately, however many PDE4 and dual PDE3/4 inhibitors have failed in early development due to low therapeutic ratios. The majority of these compounds are however orally administered and non-selective for either PDE3(A, B) or PDE4(A, B, C, D) subtypes. Developing an inhaled dual PDE3/4 inhibitor with subtype specificity may represent one strategy to improve the therapeutic index. Indeed combined inhibition of PDE3 and PDE4 inhibitor has additive and synergistic anti-inflammatory and bronchodilatory effects versus inhibition of either PDE3 or PDE4 alone. Given that synergy has been seen in terms of efficacy end points, an obvious concern is that synergy may also be observed in side effects. Interestingly, however, no synergy or additive effects with a combination of a PDE3 and PDE4 inhibitor in a cardiomyocyte assay were observed. This review will summarize the rationale for developing an inhaled dual PDE3/4 inhibitor, as a treatment for chronic obstructive pulmonary disease together with recent advances in trying to understand the pathogenesis of PDE inhibitor-induced mesenteric vasculitis (a key potential dose-limiting side effect of these agents), highlighting potential early and sensitive predictive biomarkers.This publication has 137 references indexed in Scilit:
- Occupational exposures and the risk of COPD: dusty trades revisitedThorax, 2008
- Nicotine and oxidative cigarette smoke constituents induce immune-modulatory and pro-inflammatory dendritic cell responsesMolecular Immunology, 2008
- Short‐term or long‐term treatments with a phosphodiesterase‐4 (PDE4) inhibitor result in opposing agonist‐induced Ca2+ responses in endothelial cellsBritish Journal of Pharmacology, 2008
- Survival after Lung Volume Reduction in Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Anxiogenic-Like Behavioral Phenotype of Mice Deficient in Phosphodiesterase 4B (PDE4B)Neuropsychopharmacology, 2007
- Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B–null miceJCI Insight, 2006
- Profiling human phosphodiesterase genes and splice isoformsBiochemical and Biophysical Research Communications, 2006
- Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitorsLife Sciences, 2004
- Rolipram inhibits leukocyte-endothelial cell interactionsin vivothrough P- and E-selectin downregulationBritish Journal of Pharmacology, 2002
- Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4British Journal of Pharmacology, 1998